Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB2 | P30411 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fr-173657 SCHEMBL1559539 | 1.00 | BDKRB2 (1.00) | BDKRB2 | |
| Fr-173657 SCHEMBL3718364 | 1.00 | BDKRB2 (1.00) | BDKRB2 | |
| Fr-173657 SCHEMBL7246238 | 0.99 | BDKRB2 (0.99) | BDKRB2 | |
| Fr-173657 SCHEMBL7246230 | 0.99 | BDKRB2 (0.99) | BDKRB2 | |
| SCHEMBL7742468 | 0.95 | BDKRB2 (0.91) | BDKRB2 | |
| SCHEMBL7742459 | 0.95 | BDKRB2 (0.91) | BDKRB2 | |
| SCHEMBL8812166 | 0.95 | BDKRB2 (0.90) | BDKRB2 | |
| SCHEMBL7749804 | 0.93 | BDKRB2 (0.87) | BDKRB2 | |
| SCHEMBL7748002 | 0.93 | BDKRB2 (0.87) | BDKRB2 | |
| SCHEMBL7749801 | 0.93 | BDKRB2 (0.87) | BDKRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124192-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING RNA VIRAL INFECTIONS | MODEL MEDICINES INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260102384-A1 | USE OF PIPENDOXIFENE FOR TREATING INFECTIONS OF DNA VIRUSES | MODEL MEDICINES INC (US) | 2026-04-16 | — | — | US | disclosed |
| US-12551475-B2 | Methods and compositions for treating RNA viral infections | MODEL MEDICINES, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4667008-A2 | METHODS AND COMPOSITIONS FOR TREATING RNA VIRAL INFECTIONS | Model Medicines, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250025454-A1 | USE OF PIPENDOXIFENE TO TREAT SARS-COV-2 INFECTION | MODEL MEDICINES INC (US) | 2025-01-23 | — | — | US | disclosed |
| US-20240082228-A1 | SARS-COV-2 THERAPEUTICS | MODEL MEDICINES INC (US) | 2024-03-14 | — | — | US | disclosed |
| EP-4281180-A1 | SARS-COV-2 THERAPEUTICS | Model Medicines, Inc. (US) | 2023-11-29 | — | — | EP | disclosed |
| US-20230346792-A1 | COMPOSITIONS AND METHODS FOR TREATING LUNG INFLAMMATION | HOTH THERAPEUTICS, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230248712-A1 | METHODS AND COMPOSITIONS FOR TREATING RNA VIRAL INFECTIONS | MODEL MEDICINES, INC. | 2023-08-10 | — | — | US | disclosed |
| EP-4157448-A1 | METHODS AND COMPOSITIONS FOR TREATING RNA VIRAL INFECTIONS | Model Medicines, Inc. (US) | 2023-04-05 | — | — | EP | disclosed |
| CN-113330013-B | Heterocyclic compound salt and application thereof | 石药集团中奇制药技术（石家庄）有限公司 | 2022-12-27 | — | — | CN | disclosed |
| WO-2022159763-A1 | SARS-COV-2 THERAPEUTICS | MODEL MEDICINES, INC. (US) | 2022-07-28 | — | — | WO | disclosed |
| US-20220098197-A1 | SALTS OF HETEROCYCLIC COMPOUND AND USE THEREOF | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2022-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220098197-A1 | SALTS OF HETEROCYCLIC COMPOUND AND USE THEREOF | CXCL10, CXCL8, LITAF | BDKRB2 500/4885 |
| US-12551475-B2 | Methods and compositions for treating RNA viral infections | SARS1, EIF2AK2, SNRPE | BDKRB2 3817/4885 |
| US-20260102384-A1 | USE OF PIPENDOXIFENE FOR TREATING INFECTIONS OF DNA VIRUSES | ESR1, VDR, POLL | BDKRB2 3961/4885 |
| US-20260124192-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING RNA VIRAL INFECTIONS | SARS1, NSUN2, NSUN3 | BDKRB2 4562/4885 |
| US-20250025454-A1 | USE OF PIPENDOXIFENE TO TREAT SARS-COV-2 INFECTION | EIF2AK2, ACE2, SARS1 | BDKRB2 1857/4885 |
| US-20230346792-A1 | COMPOSITIONS AND METHODS FOR TREATING LUNG INFLAMMATION | ACE2, TMPRSS2, VIPR1 | BDKRB2 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.